HomeCardiovascularStopping GLP-1s doubles diabetics’ risk of stroke, death – Italian study

Stopping GLP-1s doubles diabetics’ risk of stroke, death – Italian study

People with type 2 diabetes mellitus (T2DM) who stopped taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) had around twice the risk of heart attack, stroke or death as those who stayed on treatment, an observational study has concluded, reinforcing the recommendation that before stopping treatment, patients should consult their doctors, reports The Pharmaceutical Journal.

Publishing their findings in The Lancet Regional Health Europe, researchers analysed data from 301 diabetes clinics in Italy, collected between 2004 and 2024, which included 80 302 patients who started on a GLP-1RA and had no history of major cardiovascular events when they started treatment.

By their last visit, more than one-third of patients (39.5%, n=31,687) were still on treatment, while nearly two-thirds (60.5%, n= 48,615) had stopped, which was defined as no GLP-1RA prescription in at least two consecutive visits.

After matching 28 713 patients in each group for factors including age, BMI, HbA1c (blood glucose levels) and diabetes duration, the rate of non-fatal heart attack, non-fatal stroke or death from any cause was 3.94 per 100 years in those who stopped, compared with 1.96 in those who continued, the study results showed.

The study results also revealed that death from any cause, which was looked at as a secondary endpoint, was higher still, with 2.23 per 100 person-years in the discontinuation group compared with 0.48 per 100 person-years in the continuation group.

Such a large association “is unlikely to be explained solely by withdrawal of GLP-1RA therapy” and may be partly influenced by other factors, such as illness prompting people to stop treatment, the study authors noted.

According to the study results, the link appeared to be stronger in patients with a BMI of 30 or above (hazard ratio 2.27) than in those below 30 (hazard ratio 1.61).

The researchers also highlighted that previous studies have found that 20-50% of people stop GLP-1RA treatment within the first year, which was mostly owing to gastrointestinal side effects, cost or inconvenience.

The study authors stressed that the findings cannot show cause and effect, adding that they did not know why people stopped.

“Discontinuation may represent a higher underlying risk rather than a direct cause of increased cardiovascular risk,” they said.

They also explained that the findings may not apply to people taking GLP-1RAs for obesity without T2DM, or to tirzepatide, which was not yet available during the study.

In addition, they compared changes in risk factors, such as weight, blood pressure and cholesterol, from the start of treatment to 12 and 24 months, between people who stopped treatment and went on to have an event, and those who stopped and did not.

The study findings only demonstrated small differences, which suggests that the higher risk “may not be fully explained by deterioration of traditional risk factors alone”, the study authors noted.

Commenting on the study, Faye Riley, research communications lead at charity Diabetes UK, said the findings should be “interpreted with caution”.

“This was an observational study, so we can’t tell whether stopping taking GLP-1s directly raised people’s risk of heart attack and stroke, or if those who discontinued treatment were already experiencing health problems,” she added.

“The findings reinforce the importance of supporting people to stay on treatments that work for them. Anyone with T2DM who is considering stopping treatment should speak to their healthcare team first.”

Previous research published in January 2026 has shown that people who used weight-loss medications regained weight more rapidly than those who followed behavioural weight management programmes.

Study details

GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

Antonio Cerielloa, Francesco Prattichizzoa, Giuseppe Lucisano et al.

Published in The Lancet (Regional Health) on 9 November 2026

Summary

Background
Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) has been associated with the deterioration of cardiovascular risk factors, especially body weight. However, whether the interruption of such medication, compared with their continued use, is associated with an increased risk of cardiovascular events or mortality is unclear.

Methods
Leveraging data collected between 2004 and 2024 from 301 diabetes clinics in Italy, we conducted a retrospective cohort study in which people with type 2 diabetes (T2D), without cardiovascular diseases, and initiating a GLP-1RA were categorised as persistent users or as discontinuation group. The primary endpoint was a composite of myocardial infarction, stroke, or death from any cause, accounting for immortal time bias through the treatment-exposed person-time approach and using propensity score matching (PSM) to obtain balanced groups. Poisson and Cox regression models were used. We also examined the associated trends of risk factors levels.

Findings
Of the 80,302 subjects initiating a therapy with a GLP-1RA, 31,687 (39.5%) were still on therapy at the last visit, while 48,615 (60.5%) had discontinued treatment. Mean exposure was 2.97 ± 2.93 years among persistent users and 1.21 ± 2.13 years in the discontinuation group. Follow-up was 3.65 ± 3.03 and 4.25 ± 3.41 years, respectively. In the two groups obtained after PSM, each composed of 28,713 subjects, the IRR for the primary endpoint was 2.01 (95% confidence interval [CI] 1.77–2.28) while the relative HR was 2.03 (95% CI 1.92–2.14). The IRR for death from any cause was 4.67 (95% CI 4.11–5.30) and the corresponding HR 4.81 (95% CI 4.39–5.26). Risk factors were not meaningfully different after discontinuation in people with or without a primary endpoint.

Interpretation
In people with T2D and without previous cardiovascular disease, interrupting a therapy with GLP-1RA was associated with a higher risk of a composite of myocardial infarction, stroke, or death from any cause compared to those continuing the treatment.

 

The Lancet article – GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study (Open access)

 

The Pharmaceutical Journal article – Stopping GLP-1s linked to twice the risk of heart attack, stroke or death in type 2 diabetes (Open access)

 

See more from MedicalBrief archives:

 

Semaglutide shows heart benefits in key group – global study

 

Early-onset diabetes tied to shortened lifespan

 

GLP-1 drugs – how real are the risks?

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.